Neoepitopes and CD3-Positive and CD8-Positive Cells in Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers

Gool, Inge C. van; Bosse, Tjalling; Church, David N.

doi:10.1001/jamaoncol.2015.3900

Cited by 2 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, previous studies analysing small cohorts of mainly low or intermediate (−high) risk patients with POLEmut EC (the majority of them having low-grade EC) and no adjuvant treatment (n = 16) have reported no recurrences [11,12]. These data align with the current hypothesis that the indolent behaviour of POLEmut EC is the result of an effective antitumour immune response provoked by neoantigens produced due to the ultra-high mutational burden [21][22][23]. Accordingly, in our study none of the patients with POLEmut EC who had no adjuvant treatment (n = 26) recurred.…”

Section: Discussionsupporting

confidence: 86%

Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment

León‐Castillo

Horeweg

Peters

et al. 2022

Gynecologic Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 86%

Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment

León‐Castillo

Horeweg

Peters

et al. 2022

Gynecologic Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Perhaps the best example of an opportunity for subtype-directed care is the application of immune therapy [32,79,80]. Several studies have shown that the high TMB present in POLE-mutant and MMRd EC results in an abundance of neoepitopes/neoantigens that bind to MHC and induce an enhanced anti-tumour CD8 T-cell response [81,82].…”

Section: Impact In Recurrent Diseasementioning

confidence: 99%

The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses

McAlpine

León‐Castillo

Bosse

2018

The Journal of Pathology

Self Cite

198

151

View full text Add to dashboard Cite

Endometrial cancer is a clinically heterogeneous disease and it is becoming increasingly clear that this heterogeneity may be a function of the diversity of the underlying molecular alterations. Recent large-scale genomic studies have revealed that endometrial cancer can be divided into at least four distinct molecular subtypes, with well-described underlying genomic aberrations. These subtypes can be reliably delineated and carry significant prognostic as well as predictive information; embracing and incorporating them into clinical practice is thus attractive. The road towards the integration of molecular features into current classification systems is not without obstacles. Collaborative studies engaging research teams from across the world are working to define pragmatic assays, improve risk stratification systems by combining molecular features and traditional clinicopathological parameters, and determine how molecular classification can be optimally utilized to direct patient care. Pathologists and clinicians caring for women with endometrial cancer need to engage with and understand the possibilities and limitations of this new approach, because integration of molecular classification of endometrial cancers is anticipated to become an essential part of gynaecological pathology practice. This review will describe the challenges in current systems of endometrial carcinoma classification, the evolution of new molecular technologies that define prognostically distinct molecular subtypes, and potential applications of molecular classification as a step towards precision medicine and refining care for individuals with the most common gynaecological cancer in the developed world.

show abstract

Neoepitopes and CD3-Positive and CD8-Positive Cells in Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers

Cited by 2 publications

References 5 publications

Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment

Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment

The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses

Contact Info

Product

Resources

About